FluMist & Acambis pass advisory committee
Executive Summary
Both MedImmune's influenza virus vaccine FluMist and Acambis' live vaccinia virus smallpox vaccine ACAM2000 received positive recommendations from FDA's Vaccines and Related Biological Products Advisory Committee on May 16-17. The committee voted 9-6 that benefits of FluMist exceed risk in MedImmune's proposed population of children aged 12-59 months without a history of wheeze. ACAM2000 received unanimous approval for both safety and efficacy from the committee...